TABLE 2.
Clinical Characteristics of PAH Patients (clamp study, n=6)
| Measured Value | |
|---|---|
| NYHA Class | |
| II | 5 |
| III | 1 |
| Echocardiography | |
| RV dilation present | 5 |
| RV dysfunction present | 2 |
| RA dilation present | 3 |
| RVSP (mmHg) | 71.3±12.8 |
| Pericardial effusion present | 3 |
| NT-proBNP (pg/ml) | 80.8±24.4 |
| Medications | |
| sildenafil | 1 |
| taldalafil | 3 |
| bosentan | 1 |
| macitentan | 2 |
| treprostinil | 5 |
| 6MWT (m) | 411.7±25.6 |
| Right heart catheter data | |
| RAP (mmHg) | 8.2±1.3 |
| mPAP (mmHg) | 48.2±4.8 |
| PAWP (mmHg) | 11.5±2.4 |
| Cardiac Index (L/min/m2) | 3.08±0.18 |
| PVR (Wood units) | 6.2±0.7 |
Data represent count or mean±SEM.
PAH, pulmonary arterial hypertension; NYHA, New York Heart Association functional class; RV, right ventricle; RA, right atrium; RVSP, right ventricular systolic pressure; NT-proBNP, N-terminal pro b-type natriuretic peptide; 6MWT, 6-minute walk test; RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance.